In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET

Akio Kikuchi; Nobuyuki Okamura; Takafumi Hasegawa; Ryuichi Harada; Shoichi Watanuki; Yoshihito Funaki; Kotaro Hiraoka; Toru Baba; Naoto Sugeno; Ryuji Oshima; Shun Yoshida; Junpei Kobayashi; Michinori Ezura; Michiko Kobayashi; Ohito Tano; Shunji Mugikura; Ren Iwata; Aiko Ishiki; Katsutoshi Furukawa; Hiroyuki Arai; Shozo Furumoto; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Atsushi Takeda; Masashi Aoki

doi:10.1212/WNL.0000000000003375

In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET

Akio Kikuchi, Nobuyuki Okamura, Takafumi Hasegawa, Ryuichi Harada, Shoichi Watanuki, Yoshihito Funaki, Kotaro Hiraoka, Toru Baba, Naoto Sugeno, Ryuji Oshima, Shun Yoshida, Junpei Kobayashi, Michinori Ezura, Michiko Kobayashi, Ohito Tano, Shunji Mugikura, Ren Iwata, Aiko Ishiki, Katsutoshi Furukawa, Hiroyuki AraiShozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Atsushi Takeda, Masashi Aoki

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.

Original language	English
Pages (from-to)	2309-2316
Number of pages	8
Journal	Neurology
Volume	87
Issue number	22
DOIs	https://doi.org/10.1212/WNL.0000000000003375
Publication status	Published - 2016 Nov 29

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000003375

Fingerprint Dive into the research topics of 'In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET'. Together they form a unique fingerprint.

Cite this

Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., Hiraoka, K., Baba, T., Sugeno, N., Oshima, R., Yoshida, S., Kobayashi, J., Ezura, M., Kobayashi, M., Tano, O., Mugikura, S., Iwata, R., Ishiki, A., Furukawa, K., ... Aoki, M. (2016). In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET. Neurology, 87(22), 2309-2316. https://doi.org/10.1212/WNL.0000000000003375

In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET. / Kikuchi, Akio; Okamura, Nobuyuki; Hasegawa, Takafumi ; Harada, Ryuichi; Watanuki, Shoichi; Funaki, Yoshihito ; Hiraoka, Kotaro; Baba, Toru; Sugeno, Naoto; Oshima, Ryuji; Yoshida, Shun; Kobayashi, Junpei; Ezura, Michinori; Kobayashi, Michiko; Tano, Ohito; Mugikura, Shunji; Iwata, Ren; Ishiki, Aiko; Furukawa, Katsutoshi; Arai, Hiroyuki ; Furumoto, Shozo ; Tashiro, Manabu ; Yanai, Kazuhiko; Kudo, Yukitsuka; Takeda, Atsushi; Aoki, Masashi.

In: Neurology, Vol. 87, No. 22, 29.11.2016, p. 2309-2316.

Research output: Contribution to journal › Article › peer-review

Kikuchi, A, Okamura, N, Hasegawa, T , Harada, R, Watanuki, S, Funaki, Y , Hiraoka, K, Baba, T, Sugeno, N, Oshima, R, Yoshida, S, Kobayashi, J, Ezura, M, Kobayashi, M, Tano, O, Mugikura, S, Iwata, R, Ishiki, A, Furukawa, K, Arai, H , Furumoto, S , Tashiro, M , Yanai, K, Kudo, Y, Takeda, A & Aoki, M 2016, 'In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET', Neurology, vol. 87, no. 22, pp. 2309-2316. https://doi.org/10.1212/WNL.0000000000003375

Kikuchi, Akio ; Okamura, Nobuyuki ; Hasegawa, Takafumi ; Harada, Ryuichi ; Watanuki, Shoichi ; Funaki, Yoshihito ; Hiraoka, Kotaro ; Baba, Toru ; Sugeno, Naoto ; Oshima, Ryuji ; Yoshida, Shun ; Kobayashi, Junpei ; Ezura, Michinori ; Kobayashi, Michiko ; Tano, Ohito ; Mugikura, Shunji ; Iwata, Ren ; Ishiki, Aiko ; Furukawa, Katsutoshi ; Arai, Hiroyuki ; Furumoto, Shozo ; Tashiro, Manabu ; Yanai, Kazuhiko ; Kudo, Yukitsuka ; Takeda, Atsushi ; Aoki, Masashi. / In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET. In: Neurology. 2016 ; Vol. 87, No. 22. pp. 2309-2316.

@article{b5b3d4182fab4b409853a696d43e58e3,

title = "In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET",

abstract = "Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.",

author = "Akio Kikuchi and Nobuyuki Okamura and Takafumi Hasegawa and Ryuichi Harada and Shoichi Watanuki and Yoshihito Funaki and Kotaro Hiraoka and Toru Baba and Naoto Sugeno and Ryuji Oshima and Shun Yoshida and Junpei Kobayashi and Michinori Ezura and Michiko Kobayashi and Ohito Tano and Shunji Mugikura and Ren Iwata and Aiko Ishiki and Katsutoshi Furukawa and Hiroyuki Arai and Shozo Furumoto and Manabu Tashiro and Kazuhiko Yanai and Yukitsuka Kudo and Atsushi Takeda and Masashi Aoki",

year = "2016",

month = nov,

day = "29",

doi = "10.1212/WNL.0000000000003375",

language = "English",

volume = "87",

pages = "2309--2316",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "22",

}

TY - JOUR

T1 - In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET

AU - Kikuchi, Akio

AU - Okamura, Nobuyuki

AU - Hasegawa, Takafumi

AU - Harada, Ryuichi

AU - Watanuki, Shoichi

AU - Funaki, Yoshihito

AU - Hiraoka, Kotaro

AU - Baba, Toru

AU - Sugeno, Naoto

AU - Oshima, Ryuji

AU - Yoshida, Shun

AU - Kobayashi, Junpei

AU - Ezura, Michinori

AU - Kobayashi, Michiko

AU - Tano, Ohito

AU - Mugikura, Shunji

AU - Iwata, Ren

AU - Ishiki, Aiko

AU - Furukawa, Katsutoshi

AU - Arai, Hiroyuki

AU - Furumoto, Shozo

AU - Tashiro, Manabu

AU - Yanai, Kazuhiko

AU - Kudo, Yukitsuka

AU - Takeda, Atsushi

AU - Aoki, Masashi

PY - 2016/11/29

Y1 - 2016/11/29

N2 - Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.

AB - Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.

UR - http://www.scopus.com/inward/record.url?scp=84999873190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999873190&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003375

DO - 10.1212/WNL.0000000000003375

M3 - Article

C2 - 27794115

AN - SCOPUS:84999873190

VL - 87

SP - 2309

EP - 2316

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 22

ER -